Tracers / [18F]AmBF3-TATE
[18F]AmBF3-TATE
Also written as [18F]AMBF3-TATE; [F-18]AMBF3-TATE
- Radionuclide
- F-18 t½ 109.77 min
- Modality
- PET
- Production route
- —
- Stage
- preclinical study
- Syntheses indexed
- 4
What it is
- Compound class
- octreotate-based somatostatin analog peptide labeled via organotrifluoroborate (AmBF3) 18F-labeling
- Target / mechanism
- Somatostatin receptor subtype 2 (SSTR2) agonist binding PMID 32189151
- Clinical application
- PET imaging of somatostatin receptor-expressing neuroendocrine tumors, potential alternative to [68Ga]Ga-DOTATATE PMID 29747035
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| In-house / custom built | custom manifold | SPE | 16±1% yes | >99% | AMBF3-TATE precursor (TATE-AMBF3) | 29747035 2018 Nucl Med Biol The radiosynthesis was performed in droplets on microfluidic chips composed of Teflon-coated glass substrates. — overall decay-corrected radiochemical yield of 16±1% (n=5) in ~40 min |
| ELIXYS FLEX/CHEM Sofie Biosciences | — | SPE | 16±1% yes | >99% | AMBF3-TATE precursor (TATE-AMBF3) | 29747035 2018 Nucl Med Biol using an ELIXYS FLEX/CHEM radiosynthesizer, Sofie Biosciences, Inc., Culver City, CA, USA — overall decay-corrected radiochemical yield of 16±1% (n=5) in ~40 min |
| AllinOne (AiO) Trasis | vendor cassette | HPLC+SPE | 15 ± 4% yes | 98.0 ± 1.73% | [19F]AmBF3-TATE precursor AmbioPharm Inc. | 32189151 2020 EJNMMI Res Production of [18F]AmBF3-TATE was conducted on a Trasis AllInOne module with 36 manifold actuators and an integrated HPLC system — decay corrected radiochemical yields of 15 ± 4% |
| Manual synthesis | custom manifold | SPE | >30% yes | >99% | AMBF3-TATE precursor (50 nmol) | 30867834 2019 Theranostics [18F]AMBF3-TATE is synthesized by an IEX protocol from a custom-made peptide precursor 31. The operations of the manual procedure are performed remotely from outside the hot cell — within 25 minutes (decay-corrected RCY > 30%) |
Need this precursor?We can point you to suppliers for [18F]AmBF3-TATE, or handle the enquiry for you.
Get in touchQuality control Preliminary — inferred from compound class
- Ph. Eur. monograph
- —
- USP monograph
- —
How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); receptor ligand with a saturable target -> molar activity (rule); organic-phase radiosynthesis assumed from isotope/compound class, no synthesis data confirming it -> GC residual solvents (preliminary); conventional nucleophilic 18F-fluorination assumed from isotope/compound class, no synthesis data confirming K222 use -> Kryptofix test (preliminary)
Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived
Setting up quality control?We can help you scope the equipment needed to release [18F]AmBF3-TATE.
Get in touchNotes
Added from reverse module search (stage 6); 2 article(s) with F-18. Compound class inferred from precursor name (not stated outright) -- PMID 29747035: 'AMBF3-TATE precursor (TATE-AMBF3)'. Stage set/updated at stage 23 from PMID 29747035: 'we performed microfluidic labeling of an octreotate analog ([18F]AMBF3-TATE)'.